All In Biotech

Drug Trial Radar · NCT05887908

Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis

A Phase 3, Multi-Center, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in the Treatment of Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis, in Adults

Last checked: Nov 19, 2026Latest source record: Dec 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 614 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

614

Actual

Start

May 23, 2023

Primary completion

Nov 22, 2024

Study completion Nov 26, 2024

Sponsor

Lead sponsor
Meiji Seika Pharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Jun 5, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 3 study to evaluate the efficacy and safety of cefepime/nacubactam or aztreonam/nacubactam compared to imipenem/cilastatin in the treatment of complicated urinary tract infections (cUTI) or acute uncomplicated pyelonephritis (AP).

Conditions

  • Complicated Urinary Tract Infection
  • Acute Pyelonephritis
  • cUTI
  • AP

Interventions

  • co-administration of cefepime and nacubactamDrug

    2 g cefepime and 1 g nacubactam

  • co-administration of aztreonam and nacubactamDrug

    2 g aztreonama and 1 g nacubactam

  • imipenem/cilastatinDrug

    1 g imipenem/1 g cilastatin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Patients Who Achieve Composite Clinical and Microbiological Success at TOC (Test of Cure Visit) in the Microbiological Modified Intent-to-Treat (m-MITT) PopulationTime frame: TOC (Test of Cure visit): 7 [±2] days after EOT (end of treatment) [Day 10 to 23 after the start of treatment]

Locations

61 sites in 9 countries. Site status is shown where the registry gives one.

  • Meiji Research Site

    Pleven, Bulgaria

  • Meiji Research Site

    Rousse, Bulgaria

  • Meiji Research Site

    Silistra, Bulgaria

  • Meiji Research Site

    Sofia, Bulgaria

  • Meiji Research Site

    Beijing, China

  • Meiji Research Site

    Changchun, China

  • Meiji Research Site

    Chongqing, China

  • Meiji Research Site

    Fuyang, China

  • Meiji Research Site

    Ganzhou, China

  • Meiji Research Site

    Huaian, China

  • Meiji Research Site

    Huzhou, China

  • Meiji Research Site

    Nanchang, China

  • Meiji Research Site

    Nanning, China

  • Meiji Research Site

    Quanzhou, China

  • Meiji Research Site

    Shanghai, China

  • Meiji Research Site

    Shantou, China

  • Meiji Research Site

    Shijiazhuang, China

  • Meiji Research Site

    Taian, China

  • Meiji Research Site

    Tianjin, China

  • Meiji Research Site

    Xuancheng, China

  • Meiji Research Site

    Yunnan, China

  • Meiji Research Site

    Zhejiang, China

  • Meiji Research Site

    Zhengzhou, China

  • Meiji Research Site

    Hradec Králové, Czechia

  • Meiji Research Site

    Liberec, Czechia

  • Meiji Research Site

    Prague, Czechia

  • Meiji Research Site

    Ústí nad Labem, Czechia

  • Meiji Research Site

    Kohtla-Järve, Estonia

  • Meiji Research Site

    Tallinn, Estonia

  • Meiji Research Site

    Tartu, Estonia

  • Meiji Research Site

    Meegomäe, Võrumaa, Estonia

  • Meiji Research Site

    Kutaisi, Georgia

  • Meiji Research Site

    Rustavi, Georgia

  • Meiji Research Site

    Tbilisi, Georgia

  • Meiji Research Site

    Fukuyama, Japan

  • Meiji Research Site

    Gifu, Japan

  • Meiji Research Site

    Ibaraki-Town, Higashiibaraki-County, Japan

  • Meiji Research Site

    Iwakuni, Japan

  • Meiji Research Site

    Kanazawa, Japan

  • Meiji Research Site

    Kawachi-Nagano, Japan

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.